- Home
- ARVN vs ANIP Comparison
ARVN vs ANIP Comparison
Compare ARVN & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- ANIP
- Stock Information
- Founded
- ARVN 2015
- ANIP 2001
- Country
- ARVN United States
- ANIP United States
- Employees
- ARVN N/A
- ANIP N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- ARVN Health Care
- ANIP Health Care
- Exchange
- ARVN Nasdaq
- ANIP Nasdaq
- Market Cap
- ARVN 1.4B
- ANIP 1.2B
- IPO Year
- ARVN 2018
- ANIP N/A
- Fundamental
- Price
- ARVN $18.57
- ANIP $58.35
- Analyst Decision
- ARVN Strong Buy
- ANIP Buy
- Analyst Count
- ARVN 13
- ANIP 7
- Target Price
- ARVN $63.00
- ANIP $77.33
- AVG Volume (30 Days)
- ARVN 860.7K
- ANIP 249.7K
- Earning Date
- ARVN 02-25-2025
- ANIP 02-27-2025
- Dividend Yield
- ARVN N/A
- ANIP N/A
- EPS Growth
- ARVN N/A
- ANIP N/A
- EPS
- ARVN N/A
- ANIP N/A
- Revenue
- ARVN $161,100,000.00
- ANIP $555,456,000.00
- Revenue This Year
- ARVN $239.85
- ANIP $25.48
- Revenue Next Year
- ARVN N/A
- ANIP $20.24
- P/E Ratio
- ARVN N/A
- ANIP N/A
- Revenue Growth
- ARVN 1.07
- ANIP 23.60
- 52 Week Low
- ARVN $17.08
- ANIP $52.50
- 52 Week High
- ARVN $53.08
- ANIP $70.81
- Technical
- Relative Strength Index (RSI)
- ARVN 43.53
- ANIP 61.44
- Support Level
- ARVN $17.35
- ANIP $52.74
- Resistance Level
- ARVN $21.00
- ANIP $55.21
- Average True Range (ATR)
- ARVN 1.18
- ANIP 1.52
- MACD
- ARVN 0.12
- ANIP 0.55
- Stochastic Oscillator
- ARVN 38.01
- ANIP 86.04
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.